生血宝治疗慢性阻塞性肺疾病急性加重期疗效评估

文章信息/Info

• Title:生血宝治疗慢性阻塞性肺疾病急性加重期疗效评估

• 卷期:2024年22卷17期

• 作者:刘露，刘莉琼，钱小军

• 宜春市人民医院呼吸与危重症医学科 336000

• Author(s):Liu Lu，Liu Liqiong，Qian XiaoJun

• Department of Respiratory and Critical Care Medicine, Yichun People's Hospital 336028

• 关键词慢性阻塞性肺疾病急性加重期；生血宝；中药；疗效

• Keywords: acute exacerbation of chronic obstructive pulmonary disease; Born blood treasure; Traditional Chinese medicine; The curative effect

• 摘要:目的：比较常规治疗，常规联合生血宝治疗慢性阻塞性肺疾病急性加重的治疗效果。方法：收治慢性阻塞性肺疾病急性加重期60例患者，分为对照组、观察组。对照组予抗感染、平喘、止咳、祛痰及低流量吸氧等治疗。观察组：同对照组治疗基础上，加用生血宝合剂口服 15ml tid,两组均治疗14天后检测IL-6 、TNF-ɑ 、IFN-r、IL-4及总抗氧化物能力(TAC)水平、丙二醛(MDA)含量。结果：观察组明显低于对照组。结论：常规治疗联合生血宝治疗慢性阻塞性肺疾病急性加重期具有良好的疗效，值得进一步推广。                                                                                                                                                                                

• AbstractTo compare the therapeutic effect of conventional treatment, conventional combined with Shengxuebao in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods: 60 patients with acute exacerbation of chronic obstructive pulmonary disease were treated and divided into control group and observation group. The control group was treated with anti-infection, antiasthmatic, cough, expectorant and low flow oxygen. Observation group: On the basis of the same treatment as the control group, 15ml tid was taken orally with Shengxuebao Mixture. IL-6, TNF-R, IL-4, TAC level and malondialdehyde (MDA) content were tested in both groups after 14 days of treatment. Results: The observation group was significantly lower than the control group. Conclusion: Conventional treatment combined with Shengxuebao in the treatment of acute exacerbation of chronic obstructive pulmonary disease has a good effect, worthy of further promotion.

  慢性阻塞性肺疾病（Chronic Obstructive Pulmonary Disease，COPD）已经成为我国第三大死因[1]。临床表现为不完全可逆性气流受限，表现为咳嗽、咳痰、活动后呼吸胸闷气促等 [2-3]，分为急性加重期和稳定期，急性加重期表现为短期内症状较前明显加重，严重时伴有呼吸衰竭、肺源性心脏病等[4]。